|
1
|
Shi AA, Digumarthy SR, Temel JS, Halpern
EF, Kuester LB and Aquino SL: Does initial staging or tumor
histology better identify asymptomatic brain metastases in patients
with non-small cell lung cancer? J Thorac Oncol. 1:205–210. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Heon S, Yeap BY, Britt GJ, Costa DB, Rabin
MS, Jackman DM and Johnson BE: Development of central nervous
system metastases in patients with advanced non-small cell lung
cancer and somatic EGFR mutations treated with gefitinib or
erlotinib. Clin Cancer Res. 16:5873–5882. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Barnholtz-Sloan JS, Sloan AE, Davis FG,
Vigneau FD, Lai P and SAwaya RE: Incidence proportions of brain
metastases in patients diagnosed (1973 to 2001) in the metropolitan
detroit cancer surveillance system. J Clin Oncol. 22:2865–2872.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cox JD, Scott CB, Byhardt RW, Emami B,
Russell AH, Fu KK, Parliament MB, Komaki R and Gasper LE: Addition
of chemotherapy to radiation therapy alters failure patterns by
cell type within non-small cell carcinoma of lung (NSCCL): Analysis
of radiation therapy oncology group (RTOG) trials. Int Radiat Oncol
Biol Phys. 43:505–509. 1999. View Article : Google Scholar
|
|
5
|
Wang SY, Ye X, Ou W, Lin YB, Zhang BB and
Yang H: Risk of cerebral metastases for postoperative locally
advanced non-small-cell lung cancer. Lung Cancer. 64:238–243;.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gaspar L, Scott C, Rotman M, Asbell S,
Phillips T, Wasserman T, McKenna WG and Byhardt R: Recursive
partitioning analysis (RPA) of prognostic factors in three
radiation therapy oncology group (RTOG) brain metastases trials.
Int J Radiat Oncol Biol Phys. 37:745–751. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sperduto PW, Berkey B, Gasper LE, Mehta M
and Curran W: A new prognostic index and comparison to three other
indices for patients with brain metastases: An anlysis of 1,960
patients in the RTOG database. Int J Radiat Oncol Biol Phys.
70:510–514. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chang DB, Yang PC, Luh KT, Kuo SH, Hong RL
and Lee LN: Late survival of non-small cell lung cancer patients
with brain metastases. Influence of treatment. Chest.
101:1293–1297. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kepka L, Cieslak E, Bujko K, Fijuth J and
Wierzchowski M: Results of the whole-brain radiotherapy for
patients with brain metastases from lung cancer: The RTOG RPA
intra-classes analysis. Acta Oncol. 44:389–398. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carbonplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oisumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: Gefitinib or chemotherapy for non-small-cell lung cancer
with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shimato S, Mitsudomi T, Kosaka T, Yutabe
Y, Wakabayashi T, Mizuno M, Nakahara N, Hatano H, Natsume A, Ishii
D and Yoshida J: EGFR mutations in patients with brain metastases
from lung cancer: Association with the efficacy of gefitinib. Neuro
Oncol. 8:137–144. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim JE, Lee DH, Choi Y, Yoon DH, Kim SW,
Suh C and Lee JS: Epidermal growth factor receptor tyrosine kinase
inhibitors as a first-line therapy for never-smokers with
adenocarcinoma of the lung having asymptomatic synchronous brain
metastasis. Lung Cancer. 65:351–354. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Park SJ, Kim HT, Lee DH, Kim KP, Kim SW,
Suh C and Lee JS: Efficacy of epidermal growth factor receptor
tyrosine kinase inhibitors for brain metastasis in non-small cell
lung cancer patients harboring either exon 19 or 21 mutation. Lung
Cancer. 77:556–560. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Clay TD, Do H, Sundararajan V, Moore MM,
Conron M, Wright GM, McLachlan SA, Dobrovic A and Russell PA: The
clinical relevance of pathologic subtypes in metastatic lung
adenocarcinoma. J Thorac Oncol. 9:654–663. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Amin MB, Tamboli P, Merchant SH, Ordonez
NG, Ro J, Ayala AG and Ro JY: Micropapillary component in lung
adenocarcinoma: A distinctive histologic feature with possible
prognostic significance. Am J Surg Pathol. 26:358–364. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Travis WD BE, Burke AP, Marx A and
Nicholson AG: WHO Classification of Tumors of the Lung, Pleura,
Thymus and Heart. 4th edition. IARC press; Lyon: 2015
|
|
19
|
Mitsudomi T and Yatabe Y: Mutations of the
epidermal growth factor receptor gene and related genes as
determinants of epidermal growth factor receptor tyrosine kinase
inhibitors sensitivity in lung cancer. Cancer Sci. 98:1817–1824.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mitsudori T, Kosaka T and Yatabe Y:
Biological and clinical implications of EGFR mutations in lung
cancer. Int J Clin Oncol. 11:190–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shigematsu H, Lin L, Takahasi T, Nomura M,
Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, et al:
Clinical and biological features associated with epidermal growth
factor receptor gene mutations in lung cancers. J Natl Cancer Inst.
97:339–346. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yano M, Sasaki H, Kobayashi Y, Yukiue H,
Haneda H, Suzuki E, Endo K, Kawano O, Hara M and Fujii Y: Epidermal
growth factor receptor gene mutation and computed tomographic
findings in peripheral pulmonary adenocarcinoma. J Thorac Oncol.
1:413–416. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Doebele RC, Lu X, Sumey C, Maxson DA,
Weickhardt AJ, Oton AB, Bunn PA Jr, Barón AE, Franklin WA, Aisner
DL, et al: Oncogene status predicts patterns of metastatic spread
in treatment-naïve nonsmall cell lung cancer. Cancer.
118:4502–4511. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hendriks LE, Smit EF, Vosse BA, Mellema
WW, Heideman DA, Bootsma GP, Westenend M, Pitz C, de Vries GJ,
Houben R, et al: EGFR mutated non-small cell lung cancer patients:
More prone to development of bone and brain metastases? Lung
Cancer. 84:86–91. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rangachari D, Yamaguchi N, VanderLaan PA,
Folch E, Mahadevan A, Floyd SR, Uhlmann EJ, Wong ET, Dahlberg SE,
Huberman MS and Costa DB: Brain metastases in patients with
EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung
Cancer. 88:108–111. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Matsumoto S, Takahasi K, Iwakawa R,
Matsuno Y, Nakanishi Y, Kohno T, Shimizu E and Yokota J: Frequent
EGFR mutations in brain metastases of lung adenocarcinoma. Int J
Cancer. 119:1491–1494. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Eichler AF, Kahle KT, Wang DL, Joshi VA,
Willers H, Engelman JA, Lynch TJ and Sequist LV: EGFR mutation
status and survival after diagnosis of brain metastasis in nonsmall
cell lung cancer. Neuro Oncol. 12:1193–1199. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shin DY, Na II, Kim CH, Park S, Baek H and
Yang SH: EGFR mutation and brain metastasis in pulmonary
adenocarcinomas. J Thorac Oncol. 9:195–199. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sun M, Behrens C, Feng L, Ozburn N, Tang
X, Yin G, Komaki R, Varella-Garcia M, Hong WK, Aldape KD and
Wistuba II: HER family receptor abnormalities in lung cancer brain
metastases and corresponding primary tumors. Clin Cancer Res.
15:4829–4837. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Travis WD, Brambilla E, Noguchi M,
Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ,
Van Schil PE, et al: International association for the study of
lung cancer/American thoracic society/European respiratory society
international multidisciplinary classification of lung
adenocarcinoma. J Thorac Oncol. 6:244–285. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tsuta K, Kawago M, Inoue E, Yoshida A,
Takahashi F, Sakurai H, Watanabe S, Takeuchi M, Furuta K, Asamura H
and Tsuda H: The utility of the proposed IASLC/ATS/ERS lung
adenocarcinoma subtypes for disease prognosis and correlation of
driver gene alternations. Lung Cancer. 81:371–376. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Koga K, Hamasaki M, Kato F, Aoki M,
Hayashi H, Iwasaki A, Kataoka H and Nabeshima K: Association of
c-Met phosphorylation with micropapillary pattern and small cluster
invasion in pT1-size lung adenocarcinoma. Lung Cancer. 82:413–419.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicenter, open-label, randomized, phase 3 study.
Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Welsh JW, Komaki R, Amini A, Munsell MF,
Unger W, Allen PK, Chang JY, Wefel JS, McGovern SL, Garland LL, et
al: Phase II trial of erlotinib plus concurrent whole-brain
radiation therapy for patients with brain metastases from
non-small-cell lung cancer. J Clin Oncol. 31:895–902. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Stanic K, Zwitter M, Hitij NT, Kern I,
Sadikov A and Cufer T: Brain metastases in lung adenocarcinoma:
Impact of EGFR mutation status on incidence and survival. Radiol
Oncol. 48:173–183. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lee DW, Shin DY, Kim JW, Keam B, Kim TM,
Kim HJ, Kim DW, Wu HG, Paek SH, Kim YW, et al: Additional
prognostic role of EGFR activating mutations in lung adenocarcinoma
patients with brain metastasis: Integrating with lung specific GPA
score. Lung Cancer. 86:363–368. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sekine A, Satoh H, Iwasawa T, Tamura K,
Hayashihara K, Saito T, Kato T, Arai M, Okudela K, Ohashi K and
Ogura T: Prognostic factors for brain metastases from non-small
cell lung cancer with EGFR mutation: Influence of stable
extracranial disease and erlotinib therapy. Med Oncol. 31:2282014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tanriverdi T, Kemerdere R, Baran O,
Sayyahmelli S, Ozlen F, Isler C, Uzan M and Ozyurt E: Long-term
surgical and seizure outcomes of frontal low-grade gliomas. Int J
Surg. 33:60–64. 2016. View Article : Google Scholar : PubMed/NCBI
|
